Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Nexgard Plus Patent Expiration

Nexgard Plus is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. It is protected by 8 US drug patents filed from 2026 to 2033. All patents are active. Details of Nexgard Plus’s patents and their expiration are given below.

Filter patents by

Country : United States (US)
Patent Category : All
Drug Patent Number Drug Patent Expiry Status
Patent Data
US10596156 31 Jan, 2033 Active
US8410153 20 Jun, 2028 Active
US7964204 25 Jan, 2028 Active
US8231888 28 Dec, 2026 Active
US9095138 28 Dec, 2026 Active
US8623875 28 Dec, 2026 Active

Exclusivity Information

Nexgard Plus holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Nexgard Plus's exclusivity codes and their expiration dates are given below.

Drug Exclusivity Drug Exclusivity Expiration
NCI Jul 19, 2026

About Nexgard Plus

Nexgard Plus is a drug owned by BOEHRINGER LNGELHEIM ANIMAL HEALTH USA, INC. Nexgard Plus uses Afoxolaner, Moxidectin, Pyrantel Pamoate as the active ingredients.

Active Ingredient:

Nexgard Plus uses Afoxolaner, Moxidectin, Pyrantel Pamoate as the active ingredients. Check out other Drugs and Companies using Afoxolaner, Moxidectin, Pyrantel Pamoate ingredient.